The multifaceted role of Dectin-1 and Card9 in inflammatory bowel disease Iraqi patients
Abstract
The study aimed to investigate the role of Dectin-1 and Card-9 in pathogenicity of inflammatory bowel disease (IBD). This investigations involved 150 blood samples for IBD patients which divided in to two groups (50 for crohns disease CD (G2)and 50 for ulcerative colitis UC (G3)) .All a apparently (male and female) attended to ) Al-Kindy hospital ) in Baghdad city, department of Gastroenterology .and all of thin were diagnosis by consulters medical staff and pathologists with age range 15-65years average 40 years .in addition to 50 blood samples were collected from apparently healthy individuals as control group (G1). 10 ml were withdrawn from all participants, 5ml for the immunological study which carried by ELISA technique and 5 ml used for molecular study carried by RT-PCR. Serum was isolated than keep -20 until used m RNA were excreted The results of card9 and Dectin -1showed that, the serum concentration recorded a was highly significantly increasing level in crohns group (G2) and ulcerative colitis (G3) comparison to control group(G1) p value =0.002, 0.008 respectively also for card9 and Dectin-1. There is a non-significant in Card 9 and Dectin-1 level in the G2, G3 patients infected with Candida compared toG1, P value= 0.176 NS. 0.39 NS respectively. It has been noticed a significant Elevated Card9 andDectin-1 gene expression in patients group patients (G2) (G3) compared to (G1)p value =<0.001., <0.001** respectively Conclusion: The Dectin-1and CARD9 may has a role in the inflammatory process and might be involved in the IBD pathophysiology
Downloads
References
Abdulamir, A.S., Zaman, M.Z., Hafidh, R.R. and Bakar, A.,
The Role of Diet, Prebiotic and Probiotic in the
Development and Management of Inflammatory Bowel
Diseases (IBD). Inflammatory Bowel Disease-Advances
in Pathogenesis and Management.
Abdul-Hussein, S.S., Ali, E.N., Alkhalidi, N.M., Zaki, N.H. and
Ad'hiah, A.H., 2021. Roles of IL-17A and IL-23 in the
Pathogenesis of Ulcerative Colitis and Crohn's Disease.
Iraqi Journal of Science, pp.2526-2535.
Ad'hiah, A.H., Hessan, E.B. and Shahab, B.A., 2019.
Interleukin-1 single nucleotide polymorphisms as risk
factors for susceptibility of inflammatory bowel disease:
an Iraqi Arab population-based study. Alexandria
Journal of Medicine, 55(1), pp.1-6.
Ad'hiah, A. H., Jasim H. A. and Fadhil, A. M. A. (2008) HLA
antigens and inflammatory bowel disease in a sample of
Iraqi patients. Eastern Mediterranean Health Journal,14:
-1162
Al-Abassi, H.M., Nazal, M.F., Ad'hiah, A.H., Mushe'al, K.I., Mubarak,
I.H., Alqaisy, I.A., Saadi, A.W. and Kadhim, S.S., 2015. Serum
profile of cytokines in Iraqi inflammatory bowel disease
patients. Mustansiriya Medical Journal,14(2), p.11.
Al-Khazraji, K.A., 2011. Descriptive study of
Extragastrointestinal Manifestations of Ulcerative
Colitis and their relation to disease activity in 100 Iraqi
patients. Journal of the Faculty of Medicine Baghdad,
(1), pp.24-28.
Cheng, S.C., van de Veerdonk, F.L., Lenardon, M., Stoffels,
M., Plantinga, T., Smeekens, S., Rizzetto, L.,
Mukaremera, L., Preechasuth, K., Cavalieri, D. and
Kanneganti, T.D., 2011. The dectin-1/inflammasome
pathway is responsible for the induction of protective
T-helper 17 responses that discriminate between yeasts
and hyphae of Candida albicans. Journal of leukocyte
biology, 90(2), pp.357-366.
Dignass, A., Lindsay, J.O., Sturm, A., Windsor, A., Colombel,
J.F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G.,
Novacek, G. and Oresland, T., 2012. Second European
evidence-based consensus on the diagnosis and
management of ulcerative colitis part 2: current
management. Journal of Crohn's and Colitis, 6(10),
pp.991-1030.
Drummond, R.A. and Lionakis, M.S., 2016. Mechanistic
insights into the role of C-type lectin receptor/CARD9
signaling in human antifungal immunity. Frontiers in
cellular and infection microbiology, 6, p.39
Fadhe, I. and Mahood, W.S., 2020. Genotyping of Tumor
Necrosis Factor-? in Inflammatory Bowel Iraqi Patients.
Indian Journal of Forensic Medicine & Toxicology, 14(2),
pp.526-532.
Ghazi, H.F., Alubaidi, G.T. and Fahad, H.M., 2022. SERO¬
PREVALENCE OF EPSTEIN-BARR VIRUS IN IRAQI
INFLAMMATORY BOWEL DISEASE. Wiad Lek, 75(8),
p.2.
Hwyidii, R.R., Abbas, A.A. and AL-Khazraji, K.A., 2014. The
Role of lnterleukine-33 in Inflammatory Bowel Disease.
Al-Kindy College Medical Journal,10(2), pp.14-18.
Jebur, N.J., Kadhim, D.J. and Firhan, N.M., 2018. Belief about
Medications among Sample of Iraqi Patients with
Inflammatory Bowel Disease. Iraqi Journal of
Pharmaceutical Sciences (P-ISSN 1683-3597 E-ISSN
-3512), pp.32-41.
Ji, C., Yang, Z., Zhong, X. and Xia, J., 2021. The role and
mechanism of CARD9 gene polymorphism in diseases,
biomedical journal, 44(5), pp.560-566.
Kanvinde, S., Chhonker, Y.S., Ahmad, R., Yu, F., Sleightholm,
R., Tang, W., Jaramillo, L., Chen, Y., Sheinin, Y., Li, J. and
Murry, D.J., 2018. Pharmacokinetics and efficacy of orally
administered polymeric chloroquine as macromolecular
drug in the treatment of inflammatory bowel disease.
Acta biomaterialia, 82, pp.158-170.
Liu, X., Jiang, B., Hao, H. and Liu, Z., 2022. CARD9 Signaling,
Inflammation, and Diseases. Frontiers in Immunology,13,
p.880879. Lloyd-Price, J., Arze, C., Ananthakrishnan,
A.N., Schirmer, M., Avila-Pacheco, J., Poon, T.W.,
Andrews, E., Ajami, N.J., Bonham, K.S., Brislawn, C.J. and
Casero, D., 2019. Multi-omics of the gut microbial
ecosystem in inflammatory bowel diseases. Nature,
(7758), pp.655-662.
Luo, P., Yang, Z., Chen, B. and Zhong, X., 2020. The
multifaceted role of CARD9 in inflammatory bowel
disease. Journal of cellular and molecular medicine, 24(1),
pp.34-39.
Luo, P., Yang, Z., Chen, B. and Zhong, X., 2020. The
multifaceted role of CARD9 in inflammatory bowel
disease. Journal of cellular and molecular medicine, 24(1),
pp.34-39
Mason, K.L., Erb Downward, J.R., Falkowski, N.R., Young,
V.B., Kao, J.Y. and Huffnagle, G.B., 2012. Interplay
between the gastric bacterial microbiota and Candida
albicans during postantibiotic recolonization and
gastritis. Infection and immunity, 80(1), pp.150-158.
Mohammed, A.K., Al-Qadhi, H.I., Alkhalidi, N.M. and Fawzi,
H.A., 2020. Effectiveness of Infliximab and Adalimumab
in Iraqi patients with ulcerative colitis-Real-World Data.
Journal of Advanced Pharmacy Education & Research!
Apr-Jun,100(2), p.47.
Muhammed, H.J., Mohsun, N.N. and Al-Kaisi, A.A., 2016.
Effect of IL-17 Single Nucleotide Polymorphisms Gene on
the Risk of Developing Colorectal Cancer in Iraqi
Patients. Iraqi journal of biotechnology,15(2).Naglik, J.R., Fidel Jr, P.L. and Odds, F.C., 2008. Animal
models of mucosal Candida infection. FEMS
microbiology letters, 283(2), pp.129-139
. Plantinga, T.S., van der Velden, W.J., Ferwerda, B., van
Spriel, A.B., Adema, G., Feuth, T., Donnelly, J.P., Brown,
G.D., Kullberg, B.J., Blijlevens, N.M. and Netea, M.G.,
Early stop polymorphism in human DECTIN-1 is
associated with increased candida colonization in
hematopoietic stem cell transplant recipients. Clinical
Infectious Diseases, 49(5), pp.724-732.
Rieber, N., Gazendam, R.P., Freeman, A.F., Hsu, A.P., Collar,
A.L., Sugui, J.A., Drummond, R.A., Rongkavilit, C.,
Hoffman, K., Henderson, C. and Clark, L., 2016.
Extrapulmonary Aspergillus infection in patients with
CARD9 deficiency. JCI insight,1(17).
Rogier, G. and Vavricka, S., 2015. Exposome in IBD: recent
insights in environmental factors that influence the
onset and course of IBD. Inflammatory bowel diseases,
(2), pp.400-408.
Seelig, M.S.,1966. Mechanisms by which antibiotics increase
the incidence and severity of candidiasis and alter the
immunological defenses. Bacteriological reviews, 30(2),
pp.442-459.
Taylor PR, Brown GD, Reid DM, Willment JA, MartinezPomares L, et al. The beta-glucan receptor, dectin-1, is
predominantly expressed on the, surface of cells of the
monocyte/macrophage and neutrophil lineages. Journal
of Immunology. 2002;169:3876-3882.
Taylor, P.R., Tsoni, S.V., Willment, J.A., Dennehy, K.M., Rosas,
M., Findon, H., Haynes, K.f Steele, C., Botto, M., Gordon,
S. and Brown, G.D., 2007. Dectin-1 is required for -
glucan recognition and control of fungal infection.
Nature immunology, 8(1), pp.31-38.
Underhill, D.M. and Braun, J., 2022. Fungal microbiome in
inflammatory bowel disease: a critical assessment. The
Journal of Clinical Investigation,132(5).
Van Assche, G., Dignass, A., Panes, J., Beaugerie, L.,
Karagiannis, J., Allez, M., Ochsenkuhn, T., Orchard, T.,
Rogier, G., Louis, E. and Kupcinskas, L., 2010. The second
European evidence-based consensus on the diagnosis
and management of Crohn's disease: definitions and
diagnosis. Journal of Crohn's and Colitis, 4(1), pp.7-27.
Waly, A.H.T., Barraj, A.H. and Alrikabi, M.H., 2022.
Estimation of Calprotectin, IL-17, and IL-23 levels in the
Blood of Iraqi Patients with Crohn's Disease. The
Egyptian Journal of Hospital Medicine, 88(1), pp.3699-
Zhong, X., Chen, B., Yang, L. and Yang, Z., 2018. Molecular
and physiological roles of the adaptor protein CARD9 in
immunity. Cell death & disease, 9(2), p.52.
Zhou, G.G.D., Song, D., Choi, C.E., Pasuto, A., Sun, Q.C. and
Dai, D.F., 2018. Surge impact behavior of granular flows:
effects of water content. Landslides,15, pp.695
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
